DSM-Firmenich
Tracked across 5 events · 95 articles · First seen Jun 02, 2026 · Last active Sep 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
DSM-Firmenich, a company in nutrition, health, and beauty, announced on February 9, 2026, its intention to repurchase \u20ac500 million worth of ordinary shares to reduce its issued capital and an additional \u20ac40 million to cover…
Impact: DSM-Firmenich is repurchasing its own shares to reduce capital and cover share-based compensation plans, which is generally seen as a positive move for shareholders.
Jun 02, 2026 · 67 articles
Business
Impact: DSM-Firmenich is the grantor and organizer, reinforcing its leadership in nutrition research and public-private partnerships.
Jul 08, 2026 · 6 articles
Regulatory
Impact: DSM-Firmenich is a primary target of the CCI's price collusion investigation. The company faces potential fines and reputational damage, though it has not publicly commented.
Aug 25, 2026 · 6 articles
Business
Impact: DSM-Firmenich is a prominent company in the maleic anhydride market, influencing its development and growth.
Jun 02, 2026 · 7 articles
Business
Impact: Diego Chantrain previously led investor relations for DSM-Firmenich, providing him with relevant experience for his new role at Adecco.
Jun 25, 2026 · 9 articles
70
DSM-Firmenich announced share repurchaseDSM-Firmenich Share...
65
DSM-Firmenich announced intention to repurchaseDSM-Firmenich Share...
50
DSM-Firmenich repurchased sharesDSM-Firmenich Share...
40
DSM-Firmenich commenced repurchasing sharesDSM-Firmenich Share...
ERGEN INTELLIGENCE
Track DSM-Firmenich live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard